Welcome to our dedicated page for Cognition Therapeutics news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on Cognition Therapeutics stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company based in Pittsburgh, Pennsylvania. Established in 2007, the company is dedicated to discovering and developing small-molecule therapeutics aimed at treating age-related degenerative diseases and disorders of the central nervous system and retina.
At the heart of Cognition Therapeutics' innovation is its proprietary biology and chemistry platforms, which are utilized to identify novel drug targets and create disease-modifying therapies. The company's flagship product candidate, CT1812, is an orally administered small-molecule antagonist designed to breach the blood-brain barrier. CT1812 binds selectively to the S2R complex, potentially offering a unique therapeutic approach for patients.
Current Projects and Achievements:
- CT1812 is currently being evaluated in Phase 2 clinical trials for conditions such as Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD).
- Recent 2023 milestones include completing enrollment for the SHINE Study in mild-to-moderate Alzheimer's disease and initiating new clinical studies for early Alzheimer's and dry AMD.
- The SHIMMER study for mild-to-moderate DLB has also reached its target enrollment, with top-line results anticipated in the latter half of 2024.
The company has made significant strides in advancing its clinical programs. In 2023, the FDA approved the first disease-modifying biologics for Alzheimer’s disease, which has rejuvenated research and investment in this critical area. Cognition Therapeutics is leveraging this momentum in its ongoing research and clinical trials.
Financial Overview:
For the year ending December 31, 2023, Cognition Therapeutics reported cash and cash equivalents of approximately $29.9 million. Additional capital from a March 2024 offering has bolstered their financial position, providing the company with sufficient funds to support operations and capital expenditures through May 2025.
Research and development expenses for 2023 were $37.2 million, an increase from $30.3 million in 2022, reflecting higher costs associated with Phase 2 trials and personnel. General and administrative expenses remained relatively stable at $13.5 million.
The company continues to foster collaborations and partnerships to advance its scientific goals. Notably, the SHIMMER study is supported by a significant grant from the National Institute on Aging (NIA), totaling approximately $30 million.
For ongoing updates and detailed information about Cognition Therapeutics, visit their website at cogrx.com.
Cognition Therapeutics, Inc. completed enrollment in the Phase 2 SHIMMER study of CT1812 for mild-to-moderate dementia with Lewy bodies. Top-line results are expected in the second half of 2024. The study aims to develop a disease-modifying therapy for DLB by targeting Aβ and α-synuclein oligomers.
FAQ
What is the current stock price of Cognition Therapeutics (CGTX)?
What is the market cap of Cognition Therapeutics (CGTX)?
What does Cognition Therapeutics, Inc. specialize in?
What is CT1812?
What recent achievements has Cognition Therapeutics made?
How is Cognition Therapeutics funded?
What are the company's main areas of research?
Where is Cognition Therapeutics located?
What are the financial highlights for Cognition Therapeutics in 2023?
How does CT1812 work?
What are some key milestones expected in 2024?
How can I stay updated on Cognition Therapeutics’ progress?
